Synthetic Chemical Biology Core

项目摘要-核心C 合成化学生物学核心(SCB)成立于2016年7月，由 以新化学物质为核心的疾病途径分子分析(CMADP)分子探针 传染病生物学(CBID)药物化学核心。SCB的综合能力将实现 两个科布雷中心的具体目标。SCB在第三阶段的任务是为CMADP附属公司提供 初级教员以及堪萨斯州的其他研究人员，使用新的分子探测器 用于在体外或体内阐明特定途径的药理学工具。公务员事务局亦会致力于 实现第三阶段后的自我维持。核心将提供小分子的专业设计和合成 和多肽分子探针，重点是荧光和其他亲和力标记的生成 分子。SCB将与CMADP资助的其他核心设施协同发挥作用，包括基因组 测序核心，以确定影响体内探针功能的基因，以及KU纳米加工设施， 开发成像和化学分析设备。这一整合旨在使教员能够使用 化学生物学研究生物学问题的方法。 渣打银行在第三阶段将解决的具体目标是：(1)提供 Cobre研究人员和其他客户的兴趣；(2)提供常规和特殊多肽的合成 对调查人员；(3)提供必要的外展、行政和财政支助，以管理上述 在科布雷项目的背景下和向更大的堪萨斯州研究社区提供服务的活动 (4)继续发展足够数量的核心实验室用户，使该设施成为一个自给自足的、完整的 堪萨斯州生物医学研究基础设施的一部分。

PROJECT SUMMARY – CORE C The Synthetic Chemical Biology Core (SCB) was established in July 2016 from the merger of the Center for Molecular Analysis of Disease Pathways (CMADP) Molecular Probes Core with the newly established Chemical Biology of Infectious Disease (CBID) Medicinal Chemistry Core. The synthetic capabilities of the SCB will fulfill the specific aims of both COBRE centers. The mission for the SCB in Phase 3 is to provide CMADP-affiliated junior faculty, as well as other investigators in the state of Kansas, with novel molecular probes as pharmacological tools for in vitro or in vivo elucidation of particular pathways. The SCB will also work towards achieving self-sustainability beyond Phase 3. The Core will offer expert design and synthesis of small molecule and peptide molecular probes, with an emphasis on the generation of fluorescent and other affinity tagged molecules. The SCB will function synergistically with other CMADP-funded Core facilities, including the Genome Sequencing Core, to identify genes that impact functions of probes in vivo, and the KU Nanofabrication Facility, to develop devices for imaging and chemical analysis. This integration is designed to empower faculty to use chemical biology approaches to investigate biological problems. The specific aims that will be addressed by the SCB in Phase 3 are: (1) Provide enabling small molecules of interest to COBRE investigators and other clients; (2) Provide synthesis of conventional and specialized peptides to investigators; (3) Provide outreach, administrative, and fiscal support necessary to manage the above activities both in the context of COBRE projects and to offer services to the larger Kansas research community (4) To continue developing a critical mass of core lab users so that the facility becomes a self-sustaining, integral part of the biomedical research infrastructure in the state of Kansas.